StockMacro
Menu

Boston Scientific

$41.98 -27% in 6 monthsMarket cap $60.8B

BSX on XNYS, Health Care, Boston Scientific Corp., job postings

Measures activity, not value. Not investment advice.

Shares fell 57% in 12 months even as profit rose 26% to $3.5B.

  • GoodRevenue rose 8.9% to $21.1B over the last 12 months

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
59,000
Website
bostonscientific.com
Listed
NYSE, US
Last results
28 Oct 2026
Next results
expected around 3 Feb 2027 (an estimate: a year ago it reported on 4 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $5.1B, net income $580.0M.
Quarter to 31 Dec 2021: revenue $3.1B, net income $95.0MQuarter to 31 Dec 2021: revenue $3.1B, net income $95.0MQuarter to 31 Mar 2022: revenue $3.0B, net income $110.0MQuarter to 31 Mar 2022: revenue $3.0B, net income $110.0MQuarter to 30 Jun 2022: revenue $3.2B, net income $260.0MQuarter to 30 Jun 2022: revenue $3.2B, net income $260.0MQuarter to 30 Sep 2022: revenue $3.2B, net income $188.0MQuarter to 30 Sep 2022: revenue $3.2B, net income $188.0MQuarter to 31 Dec 2022: revenue $3.2B, net income $140.0MQuarter to 31 Dec 2022: revenue $3.2B, net income $140.0MQuarter to 31 Mar 2023: revenue $3.4B, net income $314.0MQuarter to 31 Mar 2023: revenue $3.4B, net income $314.0MQuarter to 30 Jun 2023: revenue $3.6B, net income $270.0MQuarter to 30 Jun 2023: revenue $3.6B, net income $270.0MQuarter to 30 Sep 2023: revenue $3.5B, net income $504.0MQuarter to 30 Sep 2023: revenue $3.5B, net income $504.0MQuarter to 31 Dec 2023: revenue $3.7B, net income $504.0MQuarter to 31 Dec 2023: revenue $3.7B, net income $504.0MQuarter to 31 Mar 2024: revenue $3.9B, net income $493.0MQuarter to 31 Mar 2024: revenue $3.9B, net income $493.0MQuarter to 30 Jun 2024: revenue $4.1B, net income $322.0MQuarter to 30 Jun 2024: revenue $4.1B, net income $322.0MQuarter to 30 Sep 2024: revenue $4.2B, net income $468.0MQuarter to 30 Sep 2024: revenue $4.2B, net income $468.0MQuarter to 31 Dec 2024: revenue $4.6B, net income $562.0MQuarter to 31 Dec 2024: revenue $4.6B, net income $562.0MQuarter to 31 Mar 2025: revenue $4.7B, net income $672.0MQuarter to 31 Mar 2025: revenue $4.7B, net income $672.0MQuarter to 30 Jun 2025: revenue $5.1B, net income $795.0MQuarter to 30 Jun 2025: revenue $5.1B, net income $795.0MQuarter to 30 Sep 2025: revenue $5.1B, net income $755.0MQuarter to 30 Sep 2025: revenue $5.1B, net income $755.0MQuarter to 31 Dec 2025: revenue $5.3B, net income $670.0MQuarter to 31 Dec 2025: revenue $5.3B, net income $670.0MQuarter to 31 Mar 2026: revenue $5.2B, net income $1.3BQuarter to 31 Mar 2026: revenue $5.2B, net income $1.3BQuarter to 30 Jun 2026: revenue $5.4B, net income $905.0MQuarter to 30 Jun 2026: revenue $5.4B, net income $905.0MQuarter to 30 Sep 2026: revenue $5.1B, net income $580.0MQuarter to 30 Sep 2026: revenue $5.1B, net income $580.0M
31 Dec 2021RevenueNet incometallest bar $5.4B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$5.1B$580.0M
30 Jun 2026$5.4B$905.0M
31 Mar 2026$5.2B$1.3B
31 Dec 2025$5.3B$670.0M
30 Sep 2025$5.1B$755.0M
30 Jun 2025$5.1B$795.0M
31 Mar 2025$4.7B$672.0M
31 Dec 2024$4.6B$562.0M
30 Sep 2024$4.2B$468.0M
30 Jun 2024$4.1B$322.0M
31 Mar 2024$3.9B$493.0M
31 Dec 2023$3.7B$504.0M
30 Sep 2023$3.5B$504.0M
30 Jun 2023$3.6B$270.0M
31 Mar 2023$3.4B$314.0M
31 Dec 2022$3.2B$140.0M
30 Sep 2022$3.2B$188.0M
30 Jun 2022$3.2B$260.0M
31 Mar 2022$3.0B$110.0M
31 Dec 2021$3.1B$95.0M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $21.1B $19.4B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +8.9% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $3.5B $2.8B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $2.36 $1.87
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 69.1% 68.6% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 18.7% 17.9% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 16.6% 14.4% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 14.3% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $3.3B $3.8B
CashCash, cash equivalents and short-term investments on the latest balance sheet. $609.0M $1.3B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $12.0B $11.6B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $11.3B $10.3B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.47 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $17.68
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 17.4 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 2.9 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 3.4 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.4 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Boston ScientificBSX (this company) $60.8B17.42.9+8.9%16.6%
Becton, Dickinson andBDX $58.0B61.62.8+5.2%4.5%
3MMMM $91.8B26.03.6+1.7%14.0%
ResMedRMD $33.1B20.85.8+9.0%27.8%
MedlineMDLN $32.5B36.61.1–2.9%
StrykerSYK $118.0B32.64.5+7.9%13.8%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$100K

bought $100K, sold $0

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+3.4%

1,492 13F filers vs 1,443

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

92%

1.3B shares held by 13F filers (30 Sep 2026) of 1.4B outstanding (29 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

2.4%

35.1M shares sold short (30 Oct 2026) of 1.4B outstanding (29 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.6

35.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-14%

40.7M shares sold short in the report before, 35.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

39%

39% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 32%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

-12%

99 vs 112 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+1.4%

$5.1B vs $5.1B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-0.6%

$180.0M vs $181.0M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$27.6M

the 12 months before: $27.7M

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$2.7M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

47

47 articles in the last 7 days; its usual week has 7.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

6.3×

47 articles in the last 7 days; its usual week has 7.5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Short interest 48.2M, 2.5× a year earlier
  • New institutional positions 204, 1.4× a year earlier

Price $41.98 on 20 Nov 2026, -57% over 12 months (12-month range $41.58 to $101.58)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $6.8M in the last 12 months (the 12 months before: -$115.6M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 98 published in the last 12 months, -13% on the 12 months before.
Revenue per quarter. Revenue $5.1B in the latest quarter, +1.4% on a year earlier.
Capital spending per quarter. Capital spending $180.0M in the latest quarter, -0.6% on a year earlier.
Institutional holders (13F filers). 1,492 13F filers reported holding it in the latest 13F quarter, -8.0% on a year earlier.
Federal obligations. Federal obligations: $25.2M published in the last 12 months, -24% on the 12 months before.
Lobbying spend. Lobbying spend: $2.7M published in the last 12 months, +29% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeMany funds opening a new position: many funds opening a new position, 204 vs usual 133 (2026-09-30); 1.4x the same period a year earlier
17 Nov 20268-K and other filingsBoard approved a 2027 Annual Bonus Plan and two 2027 performance share programs for eligible executive officers
7 Oct 20268-K and other filingsDirector or officer change
29 Sep 2026Sharp changeShort interest spike: short interest spike, 46.5M vs usual 25.5M (2026-09-15); 2.4x the same period a year earlier
23 Sep 20268-K and other filingsDirector or officer change
23 Sep 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Sep 2026Sharp changeShort interest spike: short interest spike, 48.2M vs usual 24.5M (2026-08-31); 2.5x the same period a year earlier
8 Sep 20268-K and other filingsMaterial cybersecurity incident
27 Jul 20268-K and other filingsRestructuring costs announced
16 Jun 2026Sharp changeShort interest spike: short interest spike, 57.5M vs usual 19.6M (2026-05-29); 3.4x the same period a year earlier
2 Jun 2026Sharp changeShort interest spike: short interest spike, 31.4M vs usual 19.5M (2026-05-15); 1.9x the same period a year earlier
22 May 2026Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 554K)
26 Feb 20268-K and other filingsA major agreement ended
23 Feb 20268-K and other filingsDirector or officer change
17 Feb 2026Sharp changeShort interest spike: short interest spike, 28.3M vs usual 18.7M (2026-01-30); 2.7x the same period a year earlier
5 Feb 20268-K and other filingsDirector or officer change
3 Feb 2026Sharp changeWikipedia attention spike: wikipedia attention spike, 6,839 vs usual 1,914.50 (2026-01-26..2026-02-01); 2.4x the same week a year earlier
13 Jan 2026Sharp changeLobbying spend jump: lobbying spend jump, 582K vs usual 401K (2025-12-31); 1.5x the same period a year earlier
12 Jan 2026Lobbying filinglobbying engagement terminated (QUICKEL CONSULTING SERVICES, LLC)
19 Nov 20258-K and other filingsDirector or officer change
23 Oct 20258-K and other filingsDirector or officer change
14 Oct 2025Sharp changeLobbying spend jump: lobbying spend jump, 582K vs usual 386K (2025-09-30); 1.4x the same period a year earlier
4 Sep 20258-K and other filingsDirector or officer change
4 Sep 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
23 Apr 20258-K and other filingsDirector or officer change
3 Apr 2025Lobbying filingnew lobbying registration (FARRAGUT PARTNERS LLP)
12 Feb 20258-K and other filingsDirector or officer change
4 Feb 2025Lobbying filingnew lobbying registration (ALSTON & BIRD LLP)
21 Jan 2025Lobbying filinglobbying engagement terminated (ALPINE GROUP PARTNERS, LLC.)
22 Nov 20248-K and other filingsDirector or officer change
22 Nov 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 Oct 2024Lobbying filingnew lobbying registration (QUICKEL CONSULTING SERVICES, LLC)
30 Jul 20248-K and other filingsDirector or officer change
10 May 20248-K and other filingsDirector or officer change
10 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 Apr 2024Lobbying filingnew lobbying registration (HOLLIER & ASSOCIATES)
31 Jan 20248-K and other filingsDirector or officer change
22 Nov 20238-K and other filingsDirector or officer change
22 Nov 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
27 Jun 20238-K and other filingsDirector or officer change
27 Jun 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 Jan 20238-K and other filingsDirector or officer change
21 Nov 20228-K and other filingsDirector or officer change
21 Nov 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
6 May 20228-K and other filingsDirector or officer change
5 Apr 20228-K and other filingsDirector or officer change
5 Apr 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Mar 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 266.0M vs usual 103.0M (2021-12-31); 1.7x the same period a year earlier
27 Jan 2022Lobbying filingnew lobbying registration (BRICK STREET STRATEGY)
18 Jan 2022Lobbying filingnew lobbying registration (LIBERTY PARTNERS GROUP, LLC)
30 Dec 2021Lobbying filinglobbying engagement terminated (10-SQUARE SOLUTIONS)
23 Nov 20218-K and other filingsDirector or officer change
23 Nov 2021Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$2.4M published
Month from 1 Jan 2022: -$596K published
Month from 1 Feb 2022: -$4.1M published
Month from 1 Mar 2022: -$1.7M published
Month from 1 Apr 2022: -$1.9M published
Month from 1 May 2022: -$296K published
Month from 1 Jun 2022: -$285K published
Month from 1 Jul 2022: -$285K published
Month from 1 Aug 2022: -$7.0M published
Month from 1 Sep 2022: -$5.4M published
Month from 1 Oct 2022: -$5.5M published
Month from 1 Nov 2022: -$6.0M published
Month from 1 Dec 2022: -$7.4M published
Month from 1 Jan 2023: -$313K published
Month from 1 Feb 2023: -$2.1M published
Month from 1 Mar 2023: -$6.0M published
Month from 1 Apr 2023: -$1.5M published
Month from 1 May 2023: -$8.4M published
Month from 1 Jun 2023: -$982K published
Month from 1 Jul 2023: -$617K published
Month from 1 Aug 2023: -$3.6M published
Month from 1 Sep 2023: -$7.6M published
Month from 1 Oct 2023: -$6.5M published
Month from 1 Nov 2023: -$7.0M published
Month from 1 Dec 2023: -$669K published
Month from 1 Jan 2024: -$7.9M published
Month from 1 Feb 2024: -$2.8M published
Month from 1 Mar 2024: -$1.4M published
Month from 1 Apr 2024: -$2.3M published
Month from 1 May 2024: -$19.8M published
Month from 1 Jun 2024: -$526K published
Month from 1 Jul 2024: -$540K published
Month from 1 Aug 2024: -$2.8M published
Month from 1 Sep 2024: -$13.8M published
Month from 1 Oct 2024: -$25.6M published
Month from 1 Nov 2024: -$18.8M published
Month from 1 Dec 2024: -$755K published
Month from 1 Jan 2025: -$2.1M published
Month from 1 Feb 2025: -$19.9M published
Month from 1 Mar 2025: -$2.3M published
Month from 1 Apr 2025: -$16.9M published
Month from 1 May 2025: -$20.0M published
Month from 1 Jun 2025: -$22.9M published
Month from 1 Jul 2025: -$6.1M published
Month from 1 Aug 2025: -$7.0M published
Month from 1 Sep 2025: -$5.3M published
Month from 1 Oct 2025: -$6.2M published
Month from 1 Nov 2025: -$6.2M published
Month from 1 Dec 2025: -$1.8M published
Month from 1 Feb 2026: -$15.0M published
Month from 1 May 2026: $554K published
Month from 1 Aug 2026: $9.5M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 27 published
Quarter from 1 Apr 2022: 27 published
Quarter from 1 Jul 2022: 42 published
Quarter from 1 Oct 2022: 38 published
Quarter from 1 Jan 2023: 18 published
Quarter from 1 Apr 2023: 21 published
Quarter from 1 Jul 2023: 33 published
Quarter from 1 Oct 2023: 18 published
Quarter from 1 Jan 2024: 9 published
Quarter from 1 Apr 2024: 29 published
Quarter from 1 Jul 2024: 47 published
Quarter from 1 Oct 2024: 17 published
Quarter from 1 Jan 2025: 26 published
Quarter from 1 Apr 2025: 24 published
Quarter from 1 Jul 2025: 39 published
Quarter from 1 Oct 2025: 24 published
Quarter from 1 Jan 2026: 19 published
Quarter from 1 Apr 2026: 26 published
Quarter from 1 Jul 2026: 37 published
Quarter from 1 Oct 2026: 16 published
Revenue per quarter
Quarter ended 31 Dec 2021: $3.1B, +15% on a year earlier; public on 24 Feb 2022
Quarter ended 31 Mar 2022: $3.0B, +10% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $3.2B, +5.4% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $3.2B, +8.1% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $3.2B, +3.7% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $3.4B, +12% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $3.6B, +11% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $3.5B, +11% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $3.7B, +15% on a year earlier; public on 21 Feb 2024
Quarter ended 31 Mar 2024: $3.9B, +14% on a year earlier; public on 2 May 2024
Quarter ended 30 Jun 2024: $4.1B, +14% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $4.2B, +19% on a year earlier; public on 2 Nov 2024
Quarter ended 31 Dec 2024: $4.6B, +22% on a year earlier; public on 19 Feb 2025
Quarter ended 31 Mar 2025: $4.7B, +21% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $5.1B, +23% on a year earlier; public on 2 Aug 2025
Quarter ended 30 Sep 2025: $5.1B, +20% on a year earlier; public on 4 Nov 2025
Quarter ended 31 Dec 2025: $5.3B, +16% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $5.2B, +12% on a year earlier; public on 2 May 2026
Quarter ended 30 Jun 2026: $5.4B, +7.5% on a year earlier; public on 4 Aug 2026
Quarter ended 30 Sep 2026: $5.1B, +1.4% on a year earlier; public on 3 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $266.0M, +67% on a year earlier; public on 24 Feb 2022
Quarter ended 31 Mar 2022: $121.0M, +61% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $105.0M, -0.9% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $150.0M, +40% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $212.0M, -20% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $111.0M, -8.3% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $143.0M, +36% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $190.0M, +27% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $267.0M, +26% on a year earlier; public on 21 Feb 2024
Quarter ended 31 Mar 2024: $179.0M, +61% on a year earlier; public on 2 May 2024
Quarter ended 30 Jun 2024: $155.0M, +8.4% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $179.0M, -5.8% on a year earlier; public on 2 Nov 2024
Quarter ended 31 Dec 2024: $277.0M, +3.7% on a year earlier; public on 19 Feb 2025
Quarter ended 31 Mar 2025: $187.0M, +4.5% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $157.0M, +1.3% on a year earlier; public on 2 Aug 2025
Quarter ended 30 Sep 2025: $181.0M, +1.1% on a year earlier; public on 4 Nov 2025
Quarter ended 31 Dec 2025: $351.0M, +27% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $177.0M, -5.3% on a year earlier; public on 2 May 2026
Quarter ended 30 Jun 2026: $195.0M, +24% on a year earlier; public on 4 Aug 2026
Quarter ended 30 Sep 2026: $180.0M, -0.6% on a year earlier; public on 3 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 775; public on 14 Feb 2022
31 Mar 2022 report: 828; public on 16 May 2022
30 Jun 2022 report: 802; public on 15 Aug 2022
30 Sep 2022 report: 770; public on 14 Nov 2022
31 Dec 2022 report: 836; public on 14 Feb 2023
31 Mar 2023 report: 913; public on 15 May 2023
30 Jun 2023 report: 967; public on 14 Aug 2023
30 Sep 2023 report: 962; public on 14 Nov 2023
31 Dec 2023 report: 1,045; public on 14 Feb 2024
31 Mar 2024 report: 1,141; public on 15 May 2024
30 Jun 2024 report: 1,235; public on 14 Aug 2024
30 Sep 2024 report: 1,314; public on 14 Nov 2024
31 Dec 2024 report: 1,423; public on 14 Feb 2025
31 Mar 2025 report: 1,551; public on 15 May 2025
30 Jun 2025 report: 1,609; public on 14 Aug 2025
30 Sep 2025 report: 1,622; public on 14 Nov 2025
31 Dec 2025 report: 1,706; public on 17 Feb 2026
31 Mar 2026 report: 1,621; public on 15 May 2026
30 Jun 2026 report: 1,443; public on 14 Aug 2026
30 Sep 2026 report: 1,492; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2021: $1.3M published
Month from 1 Dec 2021: $2.2M published
Month from 1 Jan 2022: $856K published
Month from 1 Feb 2022: $818K published
Month from 1 Mar 2022: $2.2M published
Month from 1 Apr 2022: $2.1M published
Month from 1 May 2022: $934K published
Month from 1 Jun 2022: $2.1M published
Month from 1 Jul 2022: $4.2M published
Month from 1 Aug 2022: $1.7M published
Month from 1 Sep 2022: $2.5M published
Month from 1 Oct 2022: $3.9M published
Month from 1 Nov 2022: $1.6M published
Month from 1 Dec 2022: $1.8M published
Month from 1 Jan 2023: $1.4M published
Month from 1 Feb 2023: $2.1M published
Month from 1 Mar 2023: $3.0M published
Month from 1 Apr 2023: $2.1M published
Month from 1 May 2023: $1.9M published
Month from 1 Jun 2023: $2.0M published
Month from 1 Jul 2023: $3.8M published
Month from 1 Aug 2023: $3.5M published
Month from 1 Sep 2023: $2.5M published
Month from 1 Oct 2023: $4.5M published
Month from 1 Nov 2023: $2.9M published
Month from 1 Dec 2023: $2.9M published
Month from 1 Jan 2024: $1.5M published
Month from 1 Feb 2024: $1.8M published
Month from 1 Mar 2024: $2.5M published
Month from 1 Apr 2024: $759K published
Month from 1 May 2024: $991K published
Month from 1 Jun 2024: $2.2M published
Month from 1 Jul 2024: $655K published
Month from 1 Aug 2024: $1.8M published
Month from 1 Sep 2024: $1.9M published
Month from 1 Oct 2024: $1.9M published
Month from 1 Nov 2024: $1.6M published
Month from 1 Dec 2024: $2.5M published
Month from 1 Jan 2025: $7.1M published
Month from 1 Feb 2025: $1.3M published
Month from 1 Mar 2025: $3.4M published
Month from 1 Apr 2025: $1.6M published
Month from 1 May 2025: $429K published
Month from 1 Jun 2025: $3.0M published
Month from 1 Jul 2025: $2.2M published
Month from 1 Aug 2025: $1.2M published
Month from 1 Sep 2025: $1.3M published
Month from 1 Oct 2025: $6.5M published
Month from 1 Nov 2025: $2.8M published
Month from 1 Dec 2025: $3.3M published
Month from 1 Jan 2026: $964K published
Month from 1 Feb 2026: $1.3M published
Month from 1 Mar 2026: $5.1M published
Month from 1 Apr 2026: $776K published
Month from 1 May 2026: $1.8M published
Month from 1 Jun 2026: $251K published
Month from 1 Jul 2026: $2.9M published
Month from 1 Aug 2026: $1.7M published
Month from 1 Sep 2026: $2.7M published
Month from 1 Oct 2026: $5.8M published
Month from 1 Nov 2026: -$1.3M published
Lobbying spend
Quarter from 1 Jan 2022: $390K published
Quarter from 1 Apr 2022: $380K published
Quarter from 1 Jul 2022: $380K published
Quarter from 1 Oct 2022: $380K published
Quarter from 1 Jan 2023: $380K published
Quarter from 1 Apr 2023: $380K published
Quarter from 1 Jul 2023: $380K published
Quarter from 1 Oct 2023: $380K published
Quarter from 1 Jan 2024: $380K published
Quarter from 1 Jul 2024: $380K published
Quarter from 1 Oct 2024: $790K published
Quarter from 1 Jan 2025: $392K published
Quarter from 1 Apr 2025: $442K published
Quarter from 1 Jul 2025: $642K published
Quarter from 1 Oct 2025: $642K published
Quarter from 1 Jan 2026: $642K published
Quarter from 1 Apr 2026: $702K published
Quarter from 1 Jul 2026: $702K published
Quarter from 1 Oct 2026: $682K published

What is unusual now

  • Made public in the last 90 days: it had 48.2M shares sold short in the 31 Aug 2026 report, 2.5× the same report last year; it also had 46.5M shares sold short in the 15 Sep 2026 report, 2.4× the same report last year. 3 sharp changes in all.
  • Short interest spike: had 57.5M shares sold short in the 29 May 2026 report, 3.4× the same report last year Public on 10 Jun 2026.
  • Insider net buying (open market): Insiders sold a net $6.8M in the last 12 months (the 12 months before: -$115.6M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 98 published in the last 12 months, -13% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: no sales; 1 purchase, $100K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
26 Aug 2026Susan E MoranoDirectorBuy2,040$49.22$100KForm 4
7 Aug 2026David C HabigerDirectorBuy2,100$47.59$100KForm 4
5 Aug 2026David C HabigerDirectorBuy1,182$48.13$57KForm 4
5 Aug 2026Michael F MahoneyChairman, President & CEOBuy186,240$48.33$9.0MForm 4
3 Aug 2026Edward J LudwigDirectorBuy5,000$45.48$227KForm 4
21 May 2026Edward J LudwigDirectorBuy3,580$56.68$203KForm 4
21 May 2026David C HabigerDirectorBuy4,450$56.43$251KForm 4
21 May 2026Cheryl PegusDirectorBuy1,770$56.49$100KForm 4

1,492 institutions reported shares at the end of Q3 2026, 92% of the shares outstanding; 202 opened a position, 163 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.125.6M8.66%$5.5B-4.1M-3.2%
Vanguard Capital Management LLC94.9M6.55%$4.1B-2.2M-2.2%
State Street Corp67.3M4.64%$2.9B-2.8M-4.0%
Primecap Management Co58.6M4.04%$2.6B+8.1M+16%
Vanguard Portfolio Management LLC45.4M3.13%$2.0B+15.6M+52%
Massachusetts Financial Services Co43.1M2.97%$2.3B+18.2M+73%
FMR LLC (Fidelity)40.1M2.77%$1.8B-5.6M-12%
Geode Capital Management, LLC34.5M2.38%$1.5B+1.0M+3.1%
Capital World Investors29.3M2.02%$1.3B+12.5M+74%
Arrowstreet Capital, Limited Partnership28.5M1.96%$1.2B+5.2M+22%

Federal contracts

All 14 federal contracts

1 new award in 12 months, $1.0M obligated when signed. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
1 Oct 2026Department of Veterans Affairs$1.0MTHERASPHERE Y90USAspending
2 May 2023Department of Veterans Affairs$1.7MEXPRESS REPORT: BOSTON SCIENTIFIC CONSIGNMENT AGREEMENT EXPENDITURES.USAspending
1 Oct 2022Department of Veterans Affairs$1.1Mup to $6.0MTHERASPHERE Y-90 GLASS MICROSPHERE MEDICATIONUSAspending
16 Sep 2020Department of Veterans Affairs$1.3MEXPRESS REPORT: BOSTON SCIENTIFIC CONSIGNMENT EXPENDITURESUSAspending
27 Nov 2018Department of Veterans Affairs$2.3MIGF::OT::IGF -MEDICAL SUPPLIESUSAspending
30 Aug 2011Department of Veterans AffairsEXPRESS REPORT FOR PROSTHETICS VA MEDICAL CENTERS IN VISN 12 537-1Q0039 537-1Q0041 537-1Q0113 537-1Q0819 537-1Q0821 537-1Q0824 537-1Q0958 537-1Q1112 537-1Q1211 537-1Q1320 537-1Q1321 537-1Q1654 537-1Q2014 537-1Q2016 537-Q10536 537-Q10560 537-Q10795 537-Q10991 537-Q10992 537-Q11209 537-Q11249 537-Q11988 537-Q11993 537-Q11994 537-Q12520 537-Q12521 537-Q12630 537-Q12778 537-Q12795 537-Q12803 537-Q12955 537-Q13076 537-Q13478 537-Q13947 537-Q13948 537-Q14196 537-Q14314 537-Q14335 537-Q15030 537-Q15676USAspending
23 Nov 2010Department of Veterans AffairsPACEMAKER, DEFIBRILLATOR AND LEADS TACHY FY 2011USAspending
12 Oct 2007Department of Veterans AffairsPROSTHETICS EXPRESS REPORT FY 08USAspending

Company events

All 72 company events

In 12 months: 5 director or officer changes, 3 major agreements, 1 cybersecurity incident, 1 restructuring. Results releases and routine reports are left out.

FiledWhat happenedSource
20 Nov 2026Entered underwriting agreements for $3B USD senior notes and €4.25B euro senior notes, due 2028 to 2046Same filing: took on new debt8-K
17 Nov 2026Board approved a 2027 Annual Bonus Plan and two 2027 performance share programs for eligible executive officers8-K
7 Oct 2026Director or officer change8-K
23 Sep 2026Director or officer change8-K
8 Sep 2026Material cybersecurity incident8-K
27 Jul 2026Restructuring costs announced8-K
26 Feb 2026Signed a major agreement; A major agreement endedSame filing: took on new debt8-K
23 Feb 2026Director or officer change8-K

Reported lobbying spend: $682K in Q3 2026, $702K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Dec 2025EndedQuickel Consulting Services, LLCfor Hollier & Associates On Behalf Of Boston ScientificReauthorization of TCJA; International tax proposalsTaxationFiling
1 Feb 2025NewFarragut Partners LLPfor BTG International Inc.Issues related to national stock pile and bio defenseHealth issuesFiling
1 Jan 2025NewAlston & Bird LLPfor Boston Scientific CorporationIssues concerning health care reimbursement, tax, trade.Trade, Health issues, TaxationFiling
31 Dec 2024EndedAlpine Group Partners, LLC.for Boston Scientific CorporationIssues related to treatment of chronic pain Reauthorization of the Pandemic All Hazards Preparedness Act, issues related to supply chains for medical devices H.R. 4531 SUPPORT Act Reauthorization S.2922 Advancing Research for Chronic Pain Act of 2023 New Tech Add On Payment; S. 866, the American Innovation and Jobs Act H.R. 7024, the Tax Relief for American Families and Workers Act of 2024Health issues, TaxationFiling
1 Sep 2024NewQuickel Consulting Services, LLCfor Hollier & Associates On Behalf Of Boston ScientificReauthorization of TCJA; International tax proposalsTaxationFiling
1 Mar 2024NewHollier & Associatesfor Boston ScientificReauthorization of TCJA, OECD International tax proposals, general healthcare policy mattersHealth issues, TaxationFiling
1 Jan 2022NewBrick Street Strategyfor Boston Scientific CorporationMedical supply chain and business process reforms.Health issues, VETFiling
31 Dec 2021Ended10-Square Solutionsfor Boston Scientific CorporationVA supply chain and business process reformsVETFiling

The 5 newest of 579 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

2 Jun 2026confirmed

Confirmed across sources Insiders and Short interest and volume

Boston Scientific (BSX): had 3 insiders buy $554K of its shares on the open market within 30 days (3 filings), while it had 57.5M shares sold short in the 29 May 2026 report, 3.4× the same report last year. Two unrelated kinds of activity within 25 days.

  • Insiders: Clustered insider buying, became public on 22 May 2026
  • Short interest and volume: Short interest spike, became public on 28 May 2026
  • Short interest and volume: Short interest spike, became public on 10 Jun 2026
2025-05-30: 17.0M2025-06-13: 17.5M2025-06-30: 19.0M2025-07-15: 19.6M2025-07-31: 16.3M2025-08-15: 18.6M2025-08-29: 19.0M2025-09-15: 19.0M2025-09-30: 19.4M2025-10-15: 19.6M2025-10-31: 19.5M2025-11-14: 21.1M2025-11-28: 18.7M2025-12-15: 19.1M2025-12-31: 20.0M2026-01-15: 23.4M2026-01-30: 28.3M2026-02-13: 26.6M2026-02-27: 26.3M2026-03-13: 25.4M2026-03-31: 23.5M2026-04-15: 25.6M2026-04-30: 28.6M2026-05-15: 31.4M2026-05-29: 57.5M
The 29 May 2026 report against the 24 reports before it. this reportearliernormal: 19.6M
See the evidence (3 changes)

Insiders: Clustered insider buying became public on 22 May 2026

Boston Scientific had 3 insiders buy $554K of its shares on the open market within 30 days (3 filings).

Independent buyers
3
Purchase filings (Form 4, code P)
3
Total bought
$554K
Window
22 Apr 2026 to 22 May 2026

Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

Short interest and volume: Short interest spike became public on 28 May 2026

Boston Scientific had 31.4M shares sold short in the 15 May 2026 report, 1.9× the same report last year.

This period
31.4M (the 15 May 2026 report)
Normal report (median of 24 earlier)
19.5M
Typical spread (median absolute deviation)
1.8M
How far from its usual level
+4.5
Same report last year
16.8M
History used
3,059 days
2025-05-15: 16.8M2025-05-30: 17.0M2025-06-13: 17.5M2025-06-30: 19.0M2025-07-15: 19.6M2025-07-31: 16.3M2025-08-15: 18.6M2025-08-29: 19.0M2025-09-15: 19.0M2025-09-30: 19.4M2025-10-15: 19.6M2025-10-31: 19.5M2025-11-14: 21.1M2025-11-28: 18.7M2025-12-15: 19.1M2025-12-31: 20.0M2026-01-15: 23.4M2026-01-30: 28.3M2026-02-13: 26.6M2026-02-27: 26.3M2026-03-13: 25.4M2026-03-31: 23.5M2026-04-15: 25.6M2026-04-30: 28.6M2026-05-15: 31.4M
the 15 May 2026 report24 earlier reportsnormal: 19.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Jun 2026

Boston Scientific had 57.5M shares sold short in the 29 May 2026 report, 3.4× the same report last year.

This period
57.5M (the 29 May 2026 report)
Normal report (median of 24 earlier)
19.6M
Typical spread (median absolute deviation)
1.8M
How far from its usual level
+14.3
Same report last year
17.0M
History used
3,073 days
2025-05-30: 17.0M2025-06-13: 17.5M2025-06-30: 19.0M2025-07-15: 19.6M2025-07-31: 16.3M2025-08-15: 18.6M2025-08-29: 19.0M2025-09-15: 19.0M2025-09-30: 19.4M2025-10-15: 19.6M2025-10-31: 19.5M2025-11-14: 21.1M2025-11-28: 18.7M2025-12-15: 19.1M2025-12-31: 20.0M2026-01-15: 23.4M2026-01-30: 28.3M2026-02-13: 26.6M2026-02-27: 26.3M2026-03-13: 25.4M2026-03-31: 23.5M2026-04-15: 25.6M2026-04-30: 28.6M2026-05-15: 31.4M2026-05-29: 57.5M
the 29 May 2026 report24 earlier reportsnormal: 19.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

3 Feb 2026confirmed

Confirmed across sources Attention and Lobbying and Short interest and volume

Boston Scientific (BSX): reported $582K of lobbying spend for the quarter ended 31 Dec 2025, 1.5× the same quarter last year; it also drew 6,839 Wikipedia page views in the week of 26 Jan 2026, 2.4× the same week last year; and it had 28.3M shares sold short in the 30 Jan 2026 report, 2.7× the same report last year. Three unrelated kinds of activity within 35 days.

  • Lobbying: Lobbying spend jump, became public on 12 Jan 2026
  • Attention: Wikipedia attention spike, became public on 3 Feb 2026
  • Short interest and volume: Short interest spike, became public on 11 Feb 2026
2023-12-31: $380K2024-03-31: $380K2024-06-30: $380K2024-09-30: $410K2024-12-31: $392K2025-03-31: $442K2025-06-30: $642K2025-09-30: $642K2025-12-31: $582K
The quarter ended 31 Dec 2025 against the 8 quarters before it. this quarterearliernormal: $401K
See the evidence (3 changes)

Lobbying: Lobbying spend jump became public on 12 Jan 2026

Boston Scientific reported $582K of lobbying spend for the quarter ended 31 Dec 2025, 1.5× the same quarter last year.

This period
$582K (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$401K
Typical spread (median absolute deviation)
$21K
How far from its usual level
+4.5
Same quarter last year
$392K
History used
6,301 days
2023-12-31: $380K2024-03-31: $380K2024-06-30: $380K2024-09-30: $410K2024-12-31: $392K2025-03-31: $442K2025-06-30: $642K2025-09-30: $642K2025-12-31: $582K
the quarter ended 31 Dec 20258 earlier quartersnormal: $401K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

Check it at the source: Senate/House lobbying disclosures (LDA).

Attention: Wikipedia attention spike became public on 3 Feb 2026

Boston Scientific drew 6,839 Wikipedia page views in the week of 26 Jan 2026, 2.4× the same week last year.

This period
6,839 (the week of 26 Jan 2026)
Normal week (median of 26 earlier)
1,914
Typical spread (median absolute deviation)
220
How far from its usual level
+15.1
Same week last year
2,820
History used
2,588 days
2025-07-28: 1,8282025-08-04: 2,1962025-08-11: 2,0782025-08-18: 2,9522025-08-25: 1,8592025-09-01: 1,7462025-09-08: 1,8602025-09-15: 1,8552025-09-22: 1,7402025-09-29: 1,6902025-10-06: 1,7702025-10-13: 1,8252025-10-20: 1,9692025-10-27: 1,6942025-11-03: 1,7362025-11-10: 1,6942025-11-17: 2,5212025-11-24: 3,4462025-12-01: 3,1922025-12-08: 3,1642025-12-15: 2,0792025-12-22: 1,4812025-12-29: 2,3122026-01-05: 4,4392026-01-12: 3,0022026-01-19: 2,7522026-01-26: 6,839
the week of 26 Jan 202626 earlier weeksnormal: 1,914

Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

Check it at the source: Wikimedia page view statistics.

Short interest and volume: Short interest spike became public on 11 Feb 2026

Boston Scientific had 28.3M shares sold short in the 30 Jan 2026 report, 2.7× the same report last year.

This period
28.3M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
18.7M
Typical spread (median absolute deviation)
1.5M
How far from its usual level
+4.3
Same report last year
10.4M
History used
2,954 days
2025-01-31: 10.4M2025-02-14: 11.5M2025-02-28: 12.9M2025-03-14: 12.6M2025-03-31: 13.1M2025-04-15: 14.5M2025-04-30: 15.7M2025-05-15: 16.8M2025-05-30: 17.0M2025-06-13: 17.5M2025-06-30: 19.0M2025-07-15: 19.6M2025-07-31: 16.3M2025-08-15: 18.6M2025-08-29: 19.0M2025-09-15: 19.0M2025-09-30: 19.4M2025-10-15: 19.6M2025-10-31: 19.5M2025-11-14: 21.1M2025-11-28: 18.7M2025-12-15: 19.1M2025-12-31: 20.0M2026-01-15: 23.4M2026-01-30: 28.3M
the 30 Jan 2026 report24 earlier reportsnormal: 18.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 17 Nov 2026Filings record

    Board approved a 2027 Annual Bonus Plan and two 2027 performance share programs for eligible executive officers

  2. 16 Nov 2026Institutional holdings change

    saw 204 13F filers open a new position in the quarter ended 30 Sep 2026, 1.4× the same quarter last year.

    Same quarter last year: 149; its normal quarter is 133.

    See the evidence
    This period
    204 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    133
    Typical spread (median absolute deviation)
    13.5
    How far from its usual level
    +3.5
    Same quarter last year
    149
    History used
    4,748 days
    2024-09-30: 1402024-12-31: 1112025-03-31: 1912025-06-30: 1232025-09-30: 1492025-12-31: 1222026-03-31: 1502026-06-30: 1262026-09-30: 204
    the quarter ended 30 Sep 20268 earlier quartersnormal: 133

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  3. 7 Oct 2026Filings record

    Director or officer change

  4. 7 Oct 2026Government contracts record

    BOSTON SCIENTIFIC CORP: new Department of Veterans Affairs contract 36C26227N0072 ($1.0M) (dated 1 Oct 2026)

  5. 25 Sep 2026Short interest and volume change

    had 46.5M shares sold short in the 15 Sep 2026 report, 2.4× the same report last year.

    Same report last year: 19.0M; its normal report is 25.5M.

    See the evidence
    This period
    46.5M (the 15 Sep 2026 report)
    Normal report (median of 24 earlier)
    25.5M
    Typical spread (median absolute deviation)
    3.7M
    How far from its usual level
    +3.8
    Same report last year
    19.0M
    History used
    3,182 days
    2025-09-15: 19.0M2025-09-30: 19.4M2025-10-15: 19.6M2025-10-31: 19.5M2025-11-14: 21.1M2025-11-28: 18.7M2025-12-15: 19.1M2025-12-31: 20.0M2026-01-15: 23.4M2026-01-30: 28.3M2026-02-13: 26.6M2026-02-27: 26.3M2026-03-13: 25.4M2026-03-31: 23.5M2026-04-15: 25.6M2026-04-30: 28.6M2026-05-15: 31.4M2026-05-29: 57.5M2026-06-15: 29.8M2026-06-30: 27.9M2026-07-15: 28.3M2026-07-31: 22.3M2026-08-14: 27.6M2026-08-31: 48.2M2026-09-15: 46.5M
    the 15 Sep 2026 report24 earlier reportsnormal: 25.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 23 Sep 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  7. 23 Sep 2026Filings record

    Director or officer change

  8. 11 Sep 2026Short interest and volume change

    had 48.2M shares sold short in the 31 Aug 2026 report, 2.5× the same report last year.

    Same report last year: 19.0M; its normal report is 24.5M.

    See the evidence
    This period
    48.2M (the 31 Aug 2026 report)
    Normal report (median of 24 earlier)
    24.5M
    Typical spread (median absolute deviation)
    4.0M
    How far from its usual level
    +4.0
    Same report last year
    19.0M
    History used
    3,167 days
    2025-08-29: 19.0M2025-09-15: 19.0M2025-09-30: 19.4M2025-10-15: 19.6M2025-10-31: 19.5M2025-11-14: 21.1M2025-11-28: 18.7M2025-12-15: 19.1M2025-12-31: 20.0M2026-01-15: 23.4M2026-01-30: 28.3M2026-02-13: 26.6M2026-02-27: 26.3M2026-03-13: 25.4M2026-03-31: 23.5M2026-04-15: 25.6M2026-04-30: 28.6M2026-05-15: 31.4M2026-05-29: 57.5M2026-06-15: 29.8M2026-06-30: 27.9M2026-07-15: 28.3M2026-07-31: 22.3M2026-08-14: 27.6M2026-08-31: 48.2M
    the 31 Aug 2026 report24 earlier reportsnormal: 24.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 8 Sep 2026Filings record

    Material cybersecurity incident

  10. 27 Aug 2026Insiders record

    Morano Susan E (director) bought 2,040 shares of BSX ($100,409) (dated 26 Aug 2026)

  11. 8 Aug 2026Insiders record

    Habiger David C (director) bought 2,100 shares of BSX ($99,939) (dated 7 Aug 2026)

  12. 6 Aug 2026Insiders record

    Habiger David C (director) bought 1,182 shares of BSX ($56,892) (dated 5 Aug 2026)

  13. 6 Aug 2026Insiders record

    Mahoney Michael F (Chairman, President & CEO) bought 186,240 shares of BSX ($9.0M) (dated 5 Aug 2026)

  14. 4 Aug 2026Insiders record

    LUDWIG EDWARD J (director) bought 5,000 shares of BSX ($227,400) (dated 3 Aug 2026)

  15. 27 Jul 2026Filings record

    Restructuring costs announced

  16. 10 Jun 2026Short interest and volume change

    had 57.5M shares sold short in the 29 May 2026 report, 3.4× the same report last year.

    Same report last year: 17.0M; its normal report is 19.6M.

    See the evidence
    This period
    57.5M (the 29 May 2026 report)
    Normal report (median of 24 earlier)
    19.6M
    Typical spread (median absolute deviation)
    1.8M
    How far from its usual level
    +14.3
    Same report last year
    17.0M
    History used
    3,073 days
    2025-05-30: 17.0M2025-06-13: 17.5M2025-06-30: 19.0M2025-07-15: 19.6M2025-07-31: 16.3M2025-08-15: 18.6M2025-08-29: 19.0M2025-09-15: 19.0M2025-09-30: 19.4M2025-10-15: 19.6M2025-10-31: 19.5M2025-11-14: 21.1M2025-11-28: 18.7M2025-12-15: 19.1M2025-12-31: 20.0M2026-01-15: 23.4M2026-01-30: 28.3M2026-02-13: 26.6M2026-02-27: 26.3M2026-03-13: 25.4M2026-03-31: 23.5M2026-04-15: 25.6M2026-04-30: 28.6M2026-05-15: 31.4M2026-05-29: 57.5M
    the 29 May 2026 report24 earlier reportsnormal: 19.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 2 Jun 2026several at once

    had 3 insiders buy $554K of its shares on the open market within 30 days (3 filings), while it had 57.5M shares sold short in the 29 May 2026 report, 3.4× the same report last year. Two unrelated kinds of activity within 25 days.

    See the evidence (3 changes)

    Insiders: Clustered insider buying became public on 22 May 2026

    Boston Scientific had 3 insiders buy $554K of its shares on the open market within 30 days (3 filings).

    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $554K
    Window
    22 Apr 2026 to 22 May 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

    Short interest and volume: Short interest spike became public on 28 May 2026

    Boston Scientific had 31.4M shares sold short in the 15 May 2026 report, 1.9× the same report last year.

    This period
    31.4M (the 15 May 2026 report)
    Normal report (median of 24 earlier)
    19.5M
    Typical spread (median absolute deviation)
    1.8M
    How far from its usual level
    +4.5
    Same report last year
    16.8M
    History used
    3,059 days
    2025-05-15: 16.8M2025-05-30: 17.0M2025-06-13: 17.5M2025-06-30: 19.0M2025-07-15: 19.6M2025-07-31: 16.3M2025-08-15: 18.6M2025-08-29: 19.0M2025-09-15: 19.0M2025-09-30: 19.4M2025-10-15: 19.6M2025-10-31: 19.5M2025-11-14: 21.1M2025-11-28: 18.7M2025-12-15: 19.1M2025-12-31: 20.0M2026-01-15: 23.4M2026-01-30: 28.3M2026-02-13: 26.6M2026-02-27: 26.3M2026-03-13: 25.4M2026-03-31: 23.5M2026-04-15: 25.6M2026-04-30: 28.6M2026-05-15: 31.4M
    the 15 May 2026 report24 earlier reportsnormal: 19.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Jun 2026

    Boston Scientific had 57.5M shares sold short in the 29 May 2026 report, 3.4× the same report last year.

    This period
    57.5M (the 29 May 2026 report)
    Normal report (median of 24 earlier)
    19.6M
    Typical spread (median absolute deviation)
    1.8M
    How far from its usual level
    +14.3
    Same report last year
    17.0M
    History used
    3,073 days
    2025-05-30: 17.0M2025-06-13: 17.5M2025-06-30: 19.0M2025-07-15: 19.6M2025-07-31: 16.3M2025-08-15: 18.6M2025-08-29: 19.0M2025-09-15: 19.0M2025-09-30: 19.4M2025-10-15: 19.6M2025-10-31: 19.5M2025-11-14: 21.1M2025-11-28: 18.7M2025-12-15: 19.1M2025-12-31: 20.0M2026-01-15: 23.4M2026-01-30: 28.3M2026-02-13: 26.6M2026-02-27: 26.3M2026-03-13: 25.4M2026-03-31: 23.5M2026-04-15: 25.6M2026-04-30: 28.6M2026-05-15: 31.4M2026-05-29: 57.5M
    the 29 May 2026 report24 earlier reportsnormal: 19.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  18. 28 May 2026Short interest and volume change

    had 31.4M shares sold short in the 15 May 2026 report, 1.9× the same report last year.

    Same report last year: 16.8M; its normal report is 19.5M.

    See the evidence
    This period
    31.4M (the 15 May 2026 report)
    Normal report (median of 24 earlier)
    19.5M
    Typical spread (median absolute deviation)
    1.8M
    How far from its usual level
    +4.5
    Same report last year
    16.8M
    History used
    3,059 days
    2025-05-15: 16.8M2025-05-30: 17.0M2025-06-13: 17.5M2025-06-30: 19.0M2025-07-15: 19.6M2025-07-31: 16.3M2025-08-15: 18.6M2025-08-29: 19.0M2025-09-15: 19.0M2025-09-30: 19.4M2025-10-15: 19.6M2025-10-31: 19.5M2025-11-14: 21.1M2025-11-28: 18.7M2025-12-15: 19.1M2025-12-31: 20.0M2026-01-15: 23.4M2026-01-30: 28.3M2026-02-13: 26.6M2026-02-27: 26.3M2026-03-13: 25.4M2026-03-31: 23.5M2026-04-15: 25.6M2026-04-30: 28.6M2026-05-15: 31.4M
    the 15 May 2026 report24 earlier reportsnormal: 19.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 22 May 2026Insiders change

    had 3 insiders buy $554K of its shares on the open market within 30 days (3 filings).

    Who bought: Pegus Cheryl, Habiger David C, Ludwig Edward J.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $554K
    Window
    22 Apr 2026 to 22 May 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  20. 22 May 2026Insiders record

    LUDWIG EDWARD J (director) bought 3,580 shares of BSX ($202,914) (dated 21 May 2026)

  21. 22 May 2026Insiders record

    Habiger David C (director) bought 4,450 shares of BSX ($251,110) (dated 21 May 2026)

  22. 22 May 2026Insiders record

    Pegus Cheryl (director) bought 1,770 shares of BSX ($99,987) (dated 21 May 2026)

  23. 26 Feb 2026Filings record

    A major agreement ended

  24. 23 Feb 2026Filings record

    Director or officer change

  25. 11 Feb 2026Short interest and volume change

    had 28.3M shares sold short in the 30 Jan 2026 report, 2.7× the same report last year.

    Same report last year: 10.4M; its normal report is 18.7M.

    See the evidence
    This period
    28.3M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    18.7M
    Typical spread (median absolute deviation)
    1.5M
    How far from its usual level
    +4.3
    Same report last year
    10.4M
    History used
    2,954 days
    2025-01-31: 10.4M2025-02-14: 11.5M2025-02-28: 12.9M2025-03-14: 12.6M2025-03-31: 13.1M2025-04-15: 14.5M2025-04-30: 15.7M2025-05-15: 16.8M2025-05-30: 17.0M2025-06-13: 17.5M2025-06-30: 19.0M2025-07-15: 19.6M2025-07-31: 16.3M2025-08-15: 18.6M2025-08-29: 19.0M2025-09-15: 19.0M2025-09-30: 19.4M2025-10-15: 19.6M2025-10-31: 19.5M2025-11-14: 21.1M2025-11-28: 18.7M2025-12-15: 19.1M2025-12-31: 20.0M2026-01-15: 23.4M2026-01-30: 28.3M
    the 30 Jan 2026 report24 earlier reportsnormal: 18.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 5 Feb 2026Filings record

    Director or officer change

  27. 3 Feb 2026several at once

    reported $582K of lobbying spend for the quarter ended 31 Dec 2025, 1.5× the same quarter last year; it also drew 6,839 Wikipedia page views in the week of 26 Jan 2026, 2.4× the same week last year; and it had 28.3M shares sold short in the 30 Jan 2026 report, 2.7× the same report last year. Three unrelated kinds of activity within 35 days.

    See the evidence (3 changes)

    Lobbying: Lobbying spend jump became public on 12 Jan 2026

    Boston Scientific reported $582K of lobbying spend for the quarter ended 31 Dec 2025, 1.5× the same quarter last year.

    This period
    $582K (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $401K
    Typical spread (median absolute deviation)
    $21K
    How far from its usual level
    +4.5
    Same quarter last year
    $392K
    History used
    6,301 days
    2023-12-31: $380K2024-03-31: $380K2024-06-30: $380K2024-09-30: $410K2024-12-31: $392K2025-03-31: $442K2025-06-30: $642K2025-09-30: $642K2025-12-31: $582K
    the quarter ended 31 Dec 20258 earlier quartersnormal: $401K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

    Attention: Wikipedia attention spike became public on 3 Feb 2026

    Boston Scientific drew 6,839 Wikipedia page views in the week of 26 Jan 2026, 2.4× the same week last year.

    This period
    6,839 (the week of 26 Jan 2026)
    Normal week (median of 26 earlier)
    1,914
    Typical spread (median absolute deviation)
    220
    How far from its usual level
    +15.1
    Same week last year
    2,820
    History used
    2,588 days
    2025-07-28: 1,8282025-08-04: 2,1962025-08-11: 2,0782025-08-18: 2,9522025-08-25: 1,8592025-09-01: 1,7462025-09-08: 1,8602025-09-15: 1,8552025-09-22: 1,7402025-09-29: 1,6902025-10-06: 1,7702025-10-13: 1,8252025-10-20: 1,9692025-10-27: 1,6942025-11-03: 1,7362025-11-10: 1,6942025-11-17: 2,5212025-11-24: 3,4462025-12-01: 3,1922025-12-08: 3,1642025-12-15: 2,0792025-12-22: 1,4812025-12-29: 2,3122026-01-05: 4,4392026-01-12: 3,0022026-01-19: 2,7522026-01-26: 6,839
    the week of 26 Jan 202626 earlier weeksnormal: 1,914

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

    Short interest and volume: Short interest spike became public on 11 Feb 2026

    Boston Scientific had 28.3M shares sold short in the 30 Jan 2026 report, 2.7× the same report last year.

    This period
    28.3M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    18.7M
    Typical spread (median absolute deviation)
    1.5M
    How far from its usual level
    +4.3
    Same report last year
    10.4M
    History used
    2,954 days
    2025-01-31: 10.4M2025-02-14: 11.5M2025-02-28: 12.9M2025-03-14: 12.6M2025-03-31: 13.1M2025-04-15: 14.5M2025-04-30: 15.7M2025-05-15: 16.8M2025-05-30: 17.0M2025-06-13: 17.5M2025-06-30: 19.0M2025-07-15: 19.6M2025-07-31: 16.3M2025-08-15: 18.6M2025-08-29: 19.0M2025-09-15: 19.0M2025-09-30: 19.4M2025-10-15: 19.6M2025-10-31: 19.5M2025-11-14: 21.1M2025-11-28: 18.7M2025-12-15: 19.1M2025-12-31: 20.0M2026-01-15: 23.4M2026-01-30: 28.3M
    the 30 Jan 2026 report24 earlier reportsnormal: 18.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  28. 3 Feb 2026Attention change

    drew 6,839 Wikipedia page views in the week of 26 Jan 2026, 2.4× the same week last year.

    Same week last year: 2,820; its normal week is 1,914.

    See the evidence
    This period
    6,839 (the week of 26 Jan 2026)
    Normal week (median of 26 earlier)
    1,914
    Typical spread (median absolute deviation)
    220
    How far from its usual level
    +15.1
    Same week last year
    2,820
    History used
    2,588 days
    2025-07-28: 1,8282025-08-04: 2,1962025-08-11: 2,0782025-08-18: 2,9522025-08-25: 1,8592025-09-01: 1,7462025-09-08: 1,8602025-09-15: 1,8552025-09-22: 1,7402025-09-29: 1,6902025-10-06: 1,7702025-10-13: 1,8252025-10-20: 1,9692025-10-27: 1,6942025-11-03: 1,7362025-11-10: 1,6942025-11-17: 2,5212025-11-24: 3,4462025-12-01: 3,1922025-12-08: 3,1642025-12-15: 2,0792025-12-22: 1,4812025-12-29: 2,3122026-01-05: 4,4392026-01-12: 3,0022026-01-19: 2,7522026-01-26: 6,839
    the week of 26 Jan 202626 earlier weeksnormal: 1,914

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

  29. 12 Jan 2026Lobbying change

    reported $582K of lobbying spend for the quarter ended 31 Dec 2025, 1.5× the same quarter last year.

    Same quarter last year: $392K; its normal quarter is $401K.

    See the evidence
    This period
    $582K (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $401K
    Typical spread (median absolute deviation)
    $21K
    How far from its usual level
    +4.5
    Same quarter last year
    $392K
    History used
    6,301 days
    2023-12-31: $380K2024-03-31: $380K2024-06-30: $380K2024-09-30: $410K2024-12-31: $392K2025-03-31: $442K2025-06-30: $642K2025-09-30: $642K2025-12-31: $582K
    the quarter ended 31 Dec 20258 earlier quartersnormal: $401K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  30. 12 Jan 2026Lobbying record

    HOLLIER & ASSOCIATES ON BEHALF OF BOSTON SCIENTIFIC: lobbying engagement terminated (QUICKEL CONSULTING SERVICES, LLC) (dated 31 Dec 2025)

  31. 19 Nov 2025Filings record

    Director or officer change

  32. 12 Nov 2025Institutional holdings record

    POLEN CAPITAL MANAGEMENT LLC opened a $547.0M position (2025Q3 13F)

  33. 23 Oct 2025Filings record

    Director or officer change

  34. 14 Oct 2025Lobbying change

    reported $582K of lobbying spend for the quarter ended 30 Sep 2025, 1.4× the same quarter last year.

    Same quarter last year: $410K; its normal quarter is $386K.

    See the evidence
    This period
    $582K (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $386K
    Typical spread (median absolute deviation)
    $6K
    How far from its usual level
    +5.1
    Same quarter last year
    $410K
    History used
    6,209 days
    2023-09-30: $380K2023-12-31: $380K2024-03-31: $380K2024-06-30: $380K2024-09-30: $410K2024-12-31: $392K2025-03-31: $442K2025-06-30: $642K2025-09-30: $582K
    the quarter ended 30 Sep 20258 earlier quartersnormal: $386K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  35. 4 Sep 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  36. 4 Sep 2025Filings record

    Director or officer change

  37. 13 Aug 2025Institutional holdings record

    EDGEWOOD MANAGEMENT LLC opened a $747.0M position (2025Q2 13F)

  38. 23 Apr 2025Filings record

    Director or officer change

  39. 3 Apr 2025Lobbying record

    BTG INTERNATIONAL INC.: new lobbying registration (FARRAGUT PARTNERS LLP) (dated 1 Feb 2025)

  40. 14 Feb 2025Insiders record

    Fitzgerald Joseph Michael (EVP & Group Pres, Cardiology) bought 50 shares of BSX ($4,514) (dated 13 Feb 2025)

Showing the newest 40 of 141 entries; narrow the window or the kind of data to see older ones.

Not listed: 621 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000885725
Ticker
BSX
Domain
bostonscientific.com
Employer name
Boston Scientific Corporation (1 unverified)
Hq location
MA|MARLBOROUGH|01752 (1 unverified)
Lobbying client
boston scientific, boston scientific office based facility assn obfa fka uspa, hollier and associates on behalf of boston scientific
Name
165Bio Inc., 34 Biomedical Merger Corp., 9357-1867 Quebec Inc., d/b/a Cryterion Medical Enterprise Canada, Ablacon GmbH (Germany) Ablacon SA, en liquidation and 134 more
Uei
RP18LKL9DT93, THTUFM9LVQP9, YWDHHW3DLNQ1
Wikidata
Q894585
Wikipedia
Boston Scientific
  • DOL H-1B labor condition applications and PERM certifications1493 data points1 Oct 2019 to 21 Sep 2026
  • Federal lobbying disclosures (LDA)32 records, 279 data points1 Apr 1999 to 30 Sep 2026
  • SEC Form 13F institutional holdings4 records, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)236 records4 Feb 2016 to 20 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1291 data points31 Dec 2006 to 29 Oct 2026
  • SEC Form 4 insider transactions447 records, 1368 data points6 Jan 2016 to 26 Aug 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards14 records, 16155 data points1 Oct 2007 to 20 Nov 2026
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026